This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

MLex Comment: UK's Gaviscon damage claim puts spotlight on pharma companies' generic-delaying tactics

By Emma Beddington and Lewis Crofts ( May 16, 2011, 15:27 GMT | Comment) -- A damages claim by the UK health authorities against drug manufacturer Reckitt Benckiser reveals new details of the abusive strategy the company employed to delay generic competition to its blockbuster heartburn drug, Gaviscon, and gives an insight into the often opaque mechanics of "patent life-cycle-management" strategies.A damages claim by the UK health authorities against drug manufacturer Reckitt Benckiser reveals new details of the abusive strategy the company employed to delay generic competition to its blockbuster heartburn drug, Gaviscon, and gives an insight into the often opaque mechanics of "patent life-cycle management" strategies....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections